Name: Erteberel (LY500307)
Price: 528.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Erteberel (LY500307) is a potent and selective ERβ (estrogen receptor beta) agonist (EC50 = 0.66 nM). [1]
    Estrogen receptors are nuclear hormone receptors that act as a ligand-activated transcription factor. It regulates gene expression, cell proliferation and differentiation in target tissues and involved in breast cancer, endometrial cancer and osteoporosis etc. [1]
    In transcription assay of cotransfected human prostate cancer cell line, Erteberel showed potency (EC50 = 0.66 nM), selectivity (32-fold) and full agonist function (>90% relative efficacy) to ERβ than to ERα. [1]
    In mouse model, prostate wet weight of CD-1 mice were measured following oral daily doses of Erteberel for 7 days. Results showed reduction on prostate weight in a dose-dependent manner (0.01 mg/kg – 0.05 mg/kg), and no effect on testes/seminal vesicle weight and androgens testosterone/dihydrotestosterone circulating level. [1]
- Properties
  - Categories
    
    ERβ agonist, potent and selective
    
    Alternative Name
    
    (3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
    
    CAS Number
    
    533884-09-2
    
    Molecular Formula
    
    C18H18O3
    
    Molecular Weight
    
    282.33
    
    Appearance
    
    A solid
    
    Purity
    
    98.21%
    
    Solubility
    
    insoluble in H2O; ≥14.1 mg/mL in DMSO; ≥48.3 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    C1CC2C(C1)C3=C(C=CC(=C3)O)OC2C4=CC=C(C=C4)O
    
    * For Research Use Only
- Reference
  - 1. Gangadhara R. Sareddy, Uday P. Pratap, et al. "Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells." Stem Cells. 2021 May;39(5):536-550. PMID:33470499